|Videos|December 2, 2017

Hospital Rooms Not Being Disinfected Properly: Here's Why

Edmond Hooker, MD, DrPH, discusses the reasons behind why hospital rooms are not being disinfected properly.

Edmond Hooker, MD, DrPH, professor, Health Services Administration at Xavier University, and emergency physician at the University of Cincinnati, discusses the reasons behind why hospital rooms are not being disinfected properly.

Interview Transcript (modified slightly for readability):

“Time is the big thing, okay? Hospitals are asking Environmental Services (EVS) workers to turn a room over in 20 minutes; that is not possible. If you are truly cleaning and disinfecting every part of that room, it takes almost 30 minutes just to clean the bed.

You’ve got to wipe the tops, the sides of the mattress, the bottom of the mattress, the bed deck, the handrails, up underneath, the wheels—all of that is potentially contaminated. And we’re not doing that; they usually spend about 3 minutes on the bed. Three minutes to disinfect a major piece of equipment.

Also, they use chemicals that don’t kill Clostridium difficile. Quaternary ammonium compound is the most commonly used disinfectant; it does not work for C. diff. It’s been shown not to work for C. diff on hard surfaces, but it clearly isn’t going to work on soft surfaces.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
LMN-201 Reduces C difficile Recurrence
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.